Use of single dose prophylactic magnesium sulphate in severe preeclampsia in preventing seizures

Authors

  • Shobha Bembalgi Department of Obstetrics and Gynaecology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India
  • Preet Kanwal Department of Obstetrics and Gynaecology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20162106

Keywords:

Preeclampsia, Pregnancies, Monitoring

Abstract

Background: Preeclampsia is a pregnancy specific multi organ disease process characterized by de novo development of hypertension and proteinuria after 20 weeks of gestation. Preeclampsia complicates 2-8% of pregnancies.

Methods: We have studied 100 patients with severe preeclampsia who were randomly divided into two groups. One group received 4 gm intravenous MgSO4 on admission which was prepared by diluting in 10 ml normal saline and was given over 10-12 minutes slowly with strict monitoring. 50 patients of severe pre-eclampsia with B.P>160/110 mm of Hg were given the prophylactic dose and rest 50 acted as controls. Monitoring of B.P., urine output; respiratory rate and FHS was done.

Results: We have 1 case of seizure after 8 hours of giving loading dose, which was changed to Pritchard’s regimen for further management whereas 7 patients had in the control groups. There were no cases of magnesium toxicity seen. There were no cases of maternal deaths and postpartum convulsions.

Conclusions: Single loading dose of magnesium sulphate is an efficient prophylactic in preventing eclampsia.

References

Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. Williams Obstetrics 24th edition, McGraw-Hill Companies, Inc; 2014.

Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066.

The eclampsia trial collaborative group. Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet. 1995;345:1455-63.

Pritchard JA. The use of magnesium ion in the management of eclamptogenictoxemias. Surg Gynecol Obstet. 1955;100(2):131-40.

The magpie trial collaborative group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo- controlled trial. Lancet. 2002;359:1877-90.

Begum MR, Begum A, Quadir E. Loading dose versus standard regime of magnesium sulphate in the management of eclampsia: a randomized trial. Obstet Gynaecol. 2002;28:154-9.

Suman S, Shinanjalin M, Ajit P, Uday P. Low dose magnesium sulphate therapy for eclampsia and imminent eclampsia: regimen tailored for Indian women. J Obstet Gynecol Indi. 2003;55:546-50.

Hypertension in pregnancy. American college of Obstetrics and Gynaecology (2013b) Criteria for severe preeclampsia; 2013.

Coetzee EJ, Dommisse J, Anthony J. A randomized controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre­eclampsia. An International Journal of Obstetrics and Gynaecology. 1998;105(3):300-3.

Ranganna H, Saha SC, Thami MR, Kumar P. Prophylactic magnesium sulphate in severe preeclampsia- loading dose only versus conventional 24 hours therapy of modified Pritchard's regime: a randomized trial. IOSR Journal Of Pharmacy. 2014;4(6):39-47.

Shah R, Mehendale SS. 4 gm intravenous magnesium sulphate in severe preeclampsia for prevention of eclamspia. Indian Journal of Applied Research. 2014;4(3):422-3.

Belfort MA, Anthony J, Saade GR, Allen JC. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Eng J Med. 2003;348:304-11.

Downloads

Published

2017-02-23

Issue

Section

Original Research Articles